ClinicalTrials.gg
CompletedNCT02910583CaptivateUpdated Sep 10, 2026Results posted

Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)

A Phase 2 interventional study of ibrutinib and venetoclax in Leukemia, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by Pharmacyclics LLC.. Completed at 46 sites in 6 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-10.

Primary conditionLeukemia, Lymphocytic, Chronic, B-CellRegistry: LeukemiaReclassifiedWhy we changed it
Registry
Leukemia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Leukemia, Lymphocytic, Chronic, B-Cell
Why
  1. The study's listed conditions name Leukemia, Lymphocytic, Chronic, B-Cell, a narrower term within Leukemia.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
323
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 8 open to participants now, 28 under way, 4 of them phase 3. ibrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
9th of 83
323 · median 44
Started
2016
with 13 others
Phase 2
43 of 83
6 open now
Registered
45th of 83
by date
Lead sponsor
10 of 83
Pharmacyclics LLC.

Among the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 9th largest by enrollment, is one of 14 that started in 2016, is one of 43 in phase 2, and was the 45th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

8 of the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This is a multicenter, 2-cohort Phase 2 study assessing both minimal residual disease (MRD)-guided discontinuation and fixed duration therapy with the combination of ibrutinib + venetoclax in subjects with treatment-naïve CLL or SLL.

03

Conditions studied

  • Leukemia
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma

Browse trials for

04

In context

Leukemia, Lymphocytic, Chronic, B-Cell Reclassified

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

This study's enrollment of 323 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Lead sponsor

Pharmacyclics LLC. is the lead sponsor of 54 studies on the registry; none are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 9 (90%) have results posted.

First submitted after Pharmacyclics LLC. became part of AbbVie.

Compared within Leukemia, Lymphocytic, Chronic, B-Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Leukemia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of CLL/SLL that meets 2008 International Workshop on Chronic Lymphocytic Leukemia (IWCLL) diagnostic criteria (Hallek et al), with active disease meeting at least 1 IWCLL criteria for requiring treatment.
  • Measurable nodal disease by computed tomography (CT)
  • Adequate hepatic, and renal function
  • Adequate hematologic function
  • >750/µL
  • count >30,000 /μL
  • >8.0 g/dL

Exclusion criteria

Exclusion Criteria:

  • Any prior therapy used for treatment of CLL/SLL
  • Known allergy to xanthine oxidase inhibitors and/or rasburicase for subjects at risk for tumor lysis syndrome (TLS)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
323 participants (actual)

Study arms

  • Experimental
    Fixed Duration (FD) Cohort: Open Label Ibrutinib + Venetoclax

    Participants receive 420 mg of single-agent ibrutinib for first 3 cycles followed by ibrutinib plus venetoclax combination treatment (ibrutinib 420 mg and venetoclax 400 mg orally once daily on a continuous schedule) for 12 cycles (a cycle is defined by 28 days) or until disease progression or unacceptable toxicity.

    Drug: ibrutinib · Drug: venetoclax

  • Experimental
    MRD Cohort/Confirmed Undetectable MRD (uMRD): Randomized to Ibrutinib (Blinded)

    Participants receive 420 mg of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization (pre-randomization phase). Participants with confirmed uMRD are randomized to receive ibrutinib 420 mg orally once daily on a continuous schedule until MRD-positive relapse, disease progression (PD), or unacceptable toxicity. After MRD-positive relapse or disease progression (PD) by iwCLL criteria, participants can reintroduce 400 mg venetoclax with a 5-week ramp up. If venetoclax is to be reintroduced, venetoclax treatment is to continue at the dose of 400 mg/day for up to approximately 2 years (cumulative) until PD or unacceptable toxicity.

    Drug: ibrutinib · Drug: venetoclax

  • Placebo comparator
    MRD Cohort/Confirmed uMRD: Randomized Placebo (Blinded)

    Participants receive 420 mg of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization (pre-randomization phase). Participants with confirmed uMRD are randomized to receive placebo orally once daily on a continuous schedule until MRD-positive relapse, PD or unacceptable toxicity. If MRD-positive relapse or PD is confirmed after restaging per iwCLL criteria, participants can first reintroduce oral daily ibrutinib with the option of subsequently reintroducing 400 mg venetoclax with a 5-week ramp up, if subsequent disease relapse per iwCLL criteria occurs after ibrutinib reintroduction. If venetoclax is to be reintroduced, venetoclax treatment is to continue at the dose of 400 mg/day for up to approximately 2 years (cumulative) until PD or unacceptable toxicity.

    Drug: ibrutinib · Drug: venetoclax · Drug: Placebo

  • Experimental
    MRD Cohort/uMRD Not Confirmed: Randomized to Ibrutinib (Open-Label)

    Participants receive 420 mg of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization (pre randomization phase). Participants with uMRD not confirmed are randomized to receive open-label ibrutinib 420 mg orally once daily on a continuous schedule until PD or unacceptable toxicity. In case of confirmed PD after restaging per iwCLL criteria, participants can continue ibrutinib and reintroduce venetoclax treatment. If venetoclax is to be reintroduced, venetoclax treatment is to continue at the dose of 400 mg/day for up to approximately 2 years (cumulative) until PD or unacceptable toxicity.

    Drug: ibrutinib · Drug: venetoclax

  • Experimental
    MRD Cohort/uMRD Not Confirmed: Randomized Ibrutinib + Venetoclax (Open-Label)

    Participants receive 420 mg of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization (pre randomization phase). Participants with uMRD not confirmed are randomized to receive open-label ibrutinib 420 mg and venetoclax 400 mg orally once daily on a continuous schedule until PD or unacceptable toxicity. Venetoclax was allowed for administration up to 2 years cumulatively from first dose started in the pre-randomization phase to last dose in the randomization phase.

    Drug: ibrutinib · Drug: venetoclax

Interventions

  • ibrutinib administered orally once daily (three 140 mg capsules)

  • venetoclax tablets will be administered orally once daily starting with a 5 week ramp up of 20 mg, 50 mg, 100 mg, 200 mg and 400 mg. After ramp up, venetoclax will be administered at 400 mg.

  • DrugPlacebo

    placebo capsules to match ibrutinib administered orally once daily

07

What researchers measure

Primary outcomes

  1. MRD Cohort: 1-Year Disease-Free Survival (DFS) Rate in Confirmed uMRD Randomized Participants

    DFS is defined as time from randomization date to MRD-positive relapse, or disease progression per investigator assessment (per 2008 International Workshop for Chronic Lymphocytic Leukemia \[IWCLL\] criteria \[Halleck et al\]) or death from any cause, whichever occurred first. 1-year DFS estimated using Kaplan-Meier method at 12 months landmark time.

    Time frame: 1 year after randomization

  2. FD Cohort: Complete Response Rate (CRR; Complete Response/Complete Response With Incomplete Blood Count Recovery [CR/CRi]) Rate

    CR/CRi rate is defined as the percentage of participants achieving a best overall response of complete response (CR), CR with incomplete blood count recovery (CRi) per 2008 IWCLL criteria (halleck et al.) on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurred earlier.

    Time frame: From the first dose of ibrutinib to the first confirmed PD, for a median follow-up of 69.0 months.

Secondary outcomes

  1. MRD Cohort: CRR (CR/CRi Rate)

    CR/CRi rate is defined as the percentage of participants achieving a best overall response of CR or CRi per 2008 IWCLL criteria (Halleck et al.) on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurred earlier. Median follow up duration for the individual MRD Cohort treatment arms: Confirmed uMRD Ibrutinib arm 69.1 months; Confirmed uMRD Placebo arm 67.4 months; uMRD Not Confirmed Ibrutinib arm 47.9 months; uMRD Not Confirmed Ibrutinib + Venetoclax arm 47.9 months.

    Time frame: From the first dose of ibrutinib to the first confirmed PD, for an overall median follow-up of 67.0 months. (Median follow up duration for the individual MRD Cohort treatment arms listed above.)

  2. MRD Cohort: Overall Response Rate (ORR)

    ORR, defined as the percentage of participants achieving a best overall response of protocol-specified complete response (CR), CR with incomplete blood count recovery (CRi), nodular partial response (nPR), partial response (PR), or PR with lymphocytosis (PRL) evaluated in accordance with the 2008 IWCLL criteria (Halleck et al). Participants who did not have any postbaseline response assessment were considered as non-responders. This table is based on response assessments performed on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurs earlier. Kaplan-Meier estimate. Median follow up duration for the individual MRD Cohort treatment arms: Confirmed uMRD Ibrutinib arm 69.1 months; Confirmed uMRD Placebo arm 67.4 months; uMRD Not Confirmed Ibrutinib arm 47.9 months; uMRD Not Confirmed Ibrutinib + Venetoclax arm 47.9 months.

    Time frame: From the first dose of ibrutinib to the first confirmed PD, for an overall median follow-up of 67.0 months. (Median follow up duration for the individual MRD Cohort treatment arms listed above.)

  3. MRD Cohort: Duration of Response (DOR) at 42 Months Landmark Time

    Duration of response was calculated for participants achieving a response (CR, CRi, nPR, PR) based on 2008 IWCLL response criteria (Halleck et al.) and defined as the interval between the date of initial documentation of a response including PR with lymphocytosis, until disease progression (PD) or death from any cause, whichever occurred first. As the median DOR was not reached as of 67.0 months study follow-up, the Kaplan-Meier estimate of DOR at 42 months landmark time was presented. Median follow up duration for the individual MRD Cohort treatment arms: Confirmed uMRD Ibrutinib arm 69.1 months; Confirmed uMRD Placebo arm 67.4 months; uMRD Not Confirmed Ibrutinib arm 47.9 months; uMRD Not Confirmed Ibrutinib + Venetoclax arm 47.9 months.

    Time frame: From initial documentation of a response until PD or death from any cause, whichever occurs first, for an overall median follow-up of 67.0 months. (Median follow up duration for the individual MRD Cohort treatment arms listed above.)

  4. MRD Cohort: MRD-Negativity Rate

    MRD negativity rate is defined as the percentage of participants achieving MRD negativity, which is defined as \<1 CLL cell per 10,000 leukocytes (\<1 x 10\^-4) as assessed by flow cytometry of a peripheral blood (PB) or bone marrow (BM) aspirate sample per central laboratory on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurs earlier. Median follow up duration for the individual MRD Cohort treatment arms: Confirmed uMRD Ibrutinib arm 69.1 months; Confirmed uMRD Placebo arm 67.4 months; uMRD Not Confirmed Ibrutinib arm 47.9 months; uMRD Not Confirmed Ibrutinib + Venetoclax arm 47.9 months.

    Time frame: From randomization date until before any subsequent antineoplastic therapy, for an overall median follow-up of 67.0 months. (Median follow up duration for the individual MRD Cohort treatment arms listed above.)

  5. MRD Cohort: Tumor Lysis Syndrome (TLS) Risk Reduction Rate With 3-Cycle Ibrutinib Lead-In (Percentage of Participants No Longer High Risk After 3-cycle Lead-in)

    TLS risk reduction was summarized by the percentage of participants with TLS risk reduced from high at baseline to medium or low after ibrutinib lead-in. A reduction in TLS risk from high risk to medium or low risk is clinically meaningful because there is a reduction in the extent of TLS monitoring and risk of hospitalization. TLS risk category is defined as the tumor burden category, where: Low=All lymph nodes (LN) \< 5 cm AND absolute lymphocyte count (ALC) \< 25 x 10\^9/L; Medium=Any LN 5 cm to \< 10 cm OR ALC ≥ 25 x 10\^9/L; High=Any LN ≥ 10 cm OR ALC ≥ 25 x10\^9/L AND any LN ≥ 5 cm.

    Time frame: Baseline, and last post-baseline value on or prior to venetoclax first dose date (cycle 4 day 1) or, for participants who never received venetoclax, the post-baseline value closest to cycle 4 day 1 (i.e. 84 days after the first dose date of ibrutinib).

  6. MRD Cohort: Kaplan-Meier Estimate of Progression Free Survival (PFS) Rate at 48 Months Landmark Time

    PFS was defined as time from the first dose date of study treatment until disease progression (PD) or death from any cause, whichever occurs first. Assessment of PD was conducted in accordance with the 2008 IWCLL criteria (Halleck et al). As the median PFS was not reached as of the overall median 67.0 months study follow-up, the Kaplan-Meier estimate of PFS rate at 48 months landmark time was presented. Median follow up duration for the individual MRD Cohort treatment arms: Confirmed uMRD Ibrutinib arm 69.1 months; Confirmed uMRD Placebo arm 67.4 months; uMRD Not Confirmed Ibrutinib arm 47.9 months; uMRD Not Confirmed Ibrutinib + Venetoclax arm 47.9 months.

    Time frame: From the first dose of ibrutinib to the first confirmed PD or death, for an overall median follow-up of 67.0 months. (Median follow up duration for the individual MRD Cohort treatment arms listed above.)

  7. MRD Cohort: Kaplan-Meier Estimate of Overall Survival (OS) Rate at 48 Months Landmark Time

    OS is defined as the time from the first dose date of study treatment until date of death due to any cause. As the median OS was not reached as of the overall median 67.0 months study follow-up, the Kaplan-Meier estimate of OS rate at 48 months landmark time was presented. Median follow up duration for the individual MRD Cohort treatment arms: Confirmed uMRD: Randomized to Ibrutinib=69.1 months; Confirmed uMRD: Randomized to Placebo=67.4 months; uMRD Not Confirmed: Randomized to Open-Label Ibrutinib=47.9 months; uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax=47.9 months.

    Time frame: From the first dose of ibrutinib to time of death, for an overall median follow-up of 67.0 months. (Median follow up duration for the individual MRD Cohort treatment arms listed above.)

  8. MRD Cohort: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs), and Discontinuations Due to TEAEs

    An adverse event (AE) is any untoward medical occurrence, which does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires unplanned in-patient hospitalization \>24 hours or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. Severity of events were graded according to the Common Terminology Criteria for Adverse Events version 4.03: mild=grade1, moderate=grade 2, severe=grade 3, life-threatening=grade 4, death=grade 5. Causal relation of study drug and event was assessed as not related, unlikely, possibly or probably related to the study drug.

    Time frame: From first dose until 30 days following last dose of study drug. Overall median treatment duration for the MRD cohort was 45.1 months.

  9. FD Cohort: ORR

    ORR is defined as the percentage of participants who achieve a best overall response CR, CRi, nPR, PR, or PRL as evaluated by investigator using 2008 IWCLL criteria (Halleck et al.). Participants who did not have any postbaseline response assessment were considered as non-responders. This table is based on response assessments performed on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurs earlier. Kaplan-Meier estimate.

    Time frame: From the first dose of ibrutinib to the first confirmed PD, for a median follow-up of 69.0 months.

  10. FD Cohort: DOR at 60 Months Landmark Time

    Duration of response was calculated for participants achieving a response (CR, CRi, nPR, PR) based on 2008 IWCLL response criteria (Halleck et al.) and defined as the interval between the date of initial documentation of a response including PR with lymphocytosis, until disease progression (PD) or death from any cause, whichever occurred first. As the median DOR was not reached as of the median 27.9 months study follow-up, the Kaplan-Meier estimate of DOR at 60 months landmark time was presented.

    Time frame: From initial documentation of a response until PD or death from any cause, whichever occurs first, for a median follow-up of 69.0 months.

  11. FD Cohort: MRD Negativity Rate

    MRD negativity rate is defined as the percentage of participants achieving MRD negativity, which is defined as \<1 CLL cell per 10,000 leukocytes (\<1 x 10\^-4) as assessed by flow cytometry of a peripheral blood (PB) or bone marrow (BM) aspirate sample per central laboratory on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurs earlier.

    Time frame: From randomization date until before any subsequent antineoplastic therapy, for a median follow-up of 69.0 months.

  12. FD Cohort: Kaplan-Meier Estimate of PFS Rate at 66 Months Landmark Time

    PFS was defined as time from the first dose date of study treatment until disease progression (PD) or death from any cause, whichever occurs first. Assessment of PD was conducted in accordance with the 2008 IWCLL criteria (Halleck et al). As the median PFS was not reached as of the median 69.0 months study follow-up, the Kaplan-Meier estimate of PFS rate at 66 months landmark time was presented.

    Time frame: From the first dose of ibrutinib to the first confirmed PD or death, for an median follow-up of 69.0 months.

  13. FD Cohort: Kaplan-Meier Estimate of OS Rate at 66 Months Landmark Time

    OS is defined as the time from the first dose date of study treatment until date of death due to any cause. As the median OS was not reached as of the median 69.0 months study follow-up, the Kaplan-Meier estimate of OS rate at 66 months landmark time was presented.

    Time frame: From the first dose of ibrutinib to time of death, for a median follow-up of 69.0 months.

  14. FD Cohort: TLS Risk Reduction Rate With 3-Cycle Ibrutinib Lead-In (Percentage of Participants No Longer High Risk After 3-cycle Lead-in)

    TLS risk reduction was summarized by the percentage of participants with TLS risk reduced from high at baseline to medium or low after ibrutinib lead-in. A reduction in TLS risk from high risk to medium or low risk is clinically meaningful because there is a reduction in the extent of TLS monitoring and risk of hospitalization. TLS risk category is defined as the tumor burden category, where: Low=All lymph nodes (LN) \< 5 cm AND absolute lymphocyte count (ALC) \< 25 x 10\^9/L; Medium=Any LN 5 cm to \< 10 cm OR ALC ≥ 25 x 10\^9/L; High=Any LN ≥ 10 cm OR ALC ≥ 25 x10\^9/L AND any LN ≥ 5 cm.

    Time frame: Baseline, and last post-baseline value on or prior to venetoclax first dose date (cycle 4 day 1) or, for participants who never received venetoclax, the post-baseline value closest to cycle 4 day 1 (i.e. 84 days after the first dose date of ibrutinib).

  15. FD Cohort: Percentage of Participants With TEAEs, Treatment-Emergent SAEs, and Discontinuations Due to TEAEs

    An AE is any untoward medical occurrence, which does not necessarily have a causal relationship with this treatment. An SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires unplanned in-patient hospitalization \>24 hours or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. Severity of events were graded according to the Common Terminology Criteria for Adverse Events version 4.03: mild=grade1, moderate=grade 2, severe=grade 3, life-threatening=grade 4, death=grade 5. Causal relation of study drug and event was assessed as not related, unlikely, possibly or probably related to the study drug.

    Time frame: From first dose until 30 days following last dose of study drug. Overall median treatment duration for the FD cohort was 13.8 months.

  16. MRD Cohort: Pharmacokinetics (PK) of Ibrutinib When Dosed in Combination With Venetoclax: Observed Maximum Concentration (Cmax)

    Time frame: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)

  17. MRD Cohort: PK of Ibrutinib When Dosed in Combination With Venetoclax: Time to Cmax (Tmax); Time of Last Measurable Concentration (Tlast); Terminal Elimination Half-Life (t1/2,Term)

    Time frame: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)

  18. MRD Cohort: PK of Ibrutinib When Dosed in Combination With Venetoclax: Area Under the Plasma Concentration-Time Curve (AUC) Over the Last 24-hour Dosing Interval (AUC0-24h); AUC From Time Zero to the Time of Last Quantifiable Concentration (AUClast)

    Time frame: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)

  19. MRD Cohort: PK of Ibrutinib When Dosed in Combination With Venetoclax: Terminal Elimination Rate Constant (λz)

    Time frame: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)

  20. MRD Cohort: PK of Ibrutinib When Dosed in Combination With Venetoclax: Apparent Total Clearance at Steady-State (CLss/F)

    Time frame: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)

  21. MRD Cohort: PK of Venetoclax When Dosed in Combination With Ibrutinib: Cmax

    Time frame: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)

  22. MRD Cohort: PK of Venetoclax When Dosed in Combination With Ibrutinib: Tmax

    Time frame: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)

  23. MRD Cohort: PK of Venetoclax When Dosed in Combination With Ibrutinib: AUC0-24h

    Time frame: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)

  24. MRD Cohort: PK of Venetoclax When Dosed in Combination With Ibrutinib: CLss/F

    Time frame: Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)

08

Results

Posted Feb 18, 2022

Participant flow

This study was conducted at 39 centers in the United States (US), Australia, New Zealand, Spain, and Italy.

Participant flow — Overall Study
MilestoneFixed Duration (FD) Cohort: All TreatedMinimal Residual Disease (MRD) Cohort: All Treated
Started159164
Mrd cohort/ not randomized015
Mrd cohort/ confirmed umrd: randomized to ibrutinib (blinded)043
Mrd cohort/ confirmed umrd: randomized placebo (blinded)043
Mrd cohort/umrd not confirmed: randomized to ibrutinib (open-label)031
Mrd cohort/umrd not confirmed: randomized ibrutinib + venetoclax (open-label)032
Completed133150
Not completed2614
Withdrew: Death73
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject128
Withdrew: Other, not specified63

Outcome measures

PrimaryMRD Cohort: 1-Year Disease-Free Survival (DFS) Rate in Confirmed uMRD Randomized Participants

DFS is defined as time from randomization date to MRD-positive relapse, or disease progression per investigator assessment (per 2008 International Workshop for Chronic Lymphocytic Leukemia \[IWCLL\] criteria \[Halleck et al\]) or death from any cause, whichever occurred first. 1-year DFS estimated using Kaplan-Meier method at 12 months landmark time.

Time frame:
1 year after randomization
Reported as:
Number · percentage of participants
MRD Cohort: 1-Year Disease-Free Survival (DFS) Rate in Confirmed uMRD Randomized Participants
percentage of participantsMRD Cohort/Confirmed uMRD: Randomized to Ibrutinib (Blinded)MRD Cohort/Confirmed uMRD: Randomized to Placebo (Blinded)
MRD Cohort: 1-Year Disease-Free Survival (DFS) Rate in Confirmed uMRD Randomized Participants100.0 (100.0 to 100.0)95.3 (82.7 to 98.8)
Statistical analysis
  • MRD Cohort/Confirmed uMRD: Randomized to Ibrutinib (Blinded) vs MRD Cohort/Confirmed uMRD: Randomized to Placebo (Blinded) · Z test · p = 0.1475 (P-value is from Z test for the difference of two proportions based on Kaplan-Meier estimates with standard error of each arm computed using Greenwood's formula.) · Difference in rates: 4.7 · 95% CI -1.6 to 10.9comparison: ibrutininb vs. placebo
PrimaryFD Cohort: Complete Response Rate (CRR; Complete Response/Complete Response With Incomplete Blood Count Recovery [CR/CRi]) Rate

CR/CRi rate is defined as the percentage of participants achieving a best overall response of complete response (CR), CR with incomplete blood count recovery (CRi) per 2008 IWCLL criteria (halleck et al.) on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurred earlier.

Time frame:
From the first dose of ibrutinib to the first confirmed PD, for a median follow-up of 69.0 months.
Reported as:
Number · percentage of participants
FD Cohort: Complete Response Rate (CRR; Complete Response/Complete Response With Incomplete Blood Count Recovery [CR/CRi]) Rate
percentage of participantsFD Cohort, Non-Del 17p PopulationFixed Duration (FD) Cohort: All Treated
FD Cohort: Complete Response Rate (CRR; Complete Response/Complete Response With Incomplete Blood Count Recovery [CR/CRi]) Rate58.1 (49.8 to 66.4)57.2 (49.5 to 64.9)
Statistical analysis
  • FD Cohort, Non-Del 17p Population · asymptotic test for binomial proportion · p = < 0.0001 (One-sided P-value from asymptotic test for the binomial proportion (CRR \<= 37% vs CRR \> 37%).)
SecondaryMRD Cohort: CRR (CR/CRi Rate)

CR/CRi rate is defined as the percentage of participants achieving a best overall response of CR or CRi per 2008 IWCLL criteria (Halleck et al.) on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurred earlier. Median follow up duration for the individual MRD Cohort treatment arms: Confirmed uMRD Ibrutinib arm 69.1 months; Confirmed uMRD Placebo arm 67.4 months; uMRD Not Confirmed Ibrutinib arm 47.9 months; uMRD Not Confirmed Ibrutinib + Venetoclax arm 47.9 months.

Time frame:
From the first dose of ibrutinib to the first confirmed PD, for an overall median follow-up of 67.0 months. (Median follow up duration for the individual MRD Cohort treatment arms listed above.)
Reported as:
Number · percentage of participants
MRD Cohort: CRR (CR/CRi Rate)
percentage of participantsMRD Cohort: All TreatedMRD Cohort/Confirmed uMRD: Randomized to Ibrutinib (Blinded)MRD Cohort/Confirmed uMRD: Randomized to Placebo (Blinded)MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label IbrutinibMRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax
MRD Cohort: CRR (CR/CRi Rate)66.5 (59.2 to 73.7)79.1 (66.9 to 91.2)65.1 (50.9 to 79.4)77.4 (62.7 to 92.1)56.3 (39.1 to 73.4)
SecondaryMRD Cohort: Overall Response Rate (ORR)

ORR, defined as the percentage of participants achieving a best overall response of protocol-specified complete response (CR), CR with incomplete blood count recovery (CRi), nodular partial response (nPR), partial response (PR), or PR with lymphocytosis (PRL) evaluated in accordance with the 2008 IWCLL criteria (Halleck et al). Participants who did not have any postbaseline response assessment were considered as non-responders. This table is based on response assessments performed on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurs earlier. Kaplan-Meier estimate. Median follow up duration for the individual MRD Cohort treatment arms: Confirmed uMRD Ibrutinib arm 69.1 months; Confirmed uMRD Placebo arm 67.4 months; uMRD Not Confirmed Ibrutinib arm 47.9 months; uMRD Not Confirmed Ibrutinib + Venetoclax arm 47.9 months.

Time frame:
From the first dose of ibrutinib to the first confirmed PD, for an overall median follow-up of 67.0 months. (Median follow up duration for the individual MRD Cohort treatment arms listed above.)
Reported as:
Number · percentage of participants
MRD Cohort: Overall Response Rate (ORR)
percentage of participantsMRD Cohort: All TreatedMRD Cohort/Confirmed uMRD: Randomized to Ibrutinib (Blinded)MRD Cohort/Confirmed uMRD: Randomized to Placebo (Blinded)MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label IbrutinibMRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax
MRD Cohort: Overall Response Rate (ORR)97.0 (94.3 to 99.6)100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)
SecondaryMRD Cohort: Duration of Response (DOR) at 42 Months Landmark Time

Duration of response was calculated for participants achieving a response (CR, CRi, nPR, PR) based on 2008 IWCLL response criteria (Halleck et al.) and defined as the interval between the date of initial documentation of a response including PR with lymphocytosis, until disease progression (PD) or death from any cause, whichever occurred first. As the median DOR was not reached as of 67.0 months study follow-up, the Kaplan-Meier estimate of DOR at 42 months landmark time was presented. Median follow up duration for the individual MRD Cohort treatment arms: Confirmed uMRD Ibrutinib arm 69.1 months; Confirmed uMRD Placebo arm 67.4 months; uMRD Not Confirmed Ibrutinib arm 47.9 months; uMRD Not Confirmed Ibrutinib + Venetoclax arm 47.9 months.

Time frame:
From initial documentation of a response until PD or death from any cause, whichever occurs first, for an overall median follow-up of 67.0 months. (Median follow up duration for the individual MRD Cohort treatment arms listed above.)
Reported as:
Number · percentage of participants
MRD Cohort: Duration of Response (DOR) at 42 Months Landmark Time
percentage of participantsMRD Cohort: All TreatedMRD Cohort/Confirmed uMRD: Randomized to Ibrutinib (Blinded)MRD Cohort/Confirmed uMRD: Randomized to Placebo (Blinded)MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label IbrutinibMRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax
MRD Cohort: Duration of Response (DOR) at 42 Months Landmark Time93.5 (88.2 to 96.4)97.6 (84.3 to 99.7)93.0 (79.7 to 97.7)96.7 (78.6 to 99.5)93.2 (75.5 to 98.3)
SecondaryMRD Cohort: MRD-Negativity Rate

MRD negativity rate is defined as the percentage of participants achieving MRD negativity, which is defined as \<1 CLL cell per 10,000 leukocytes (\<1 x 10\^-4) as assessed by flow cytometry of a peripheral blood (PB) or bone marrow (BM) aspirate sample per central laboratory on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurs earlier. Median follow up duration for the individual MRD Cohort treatment arms: Confirmed uMRD Ibrutinib arm 69.1 months; Confirmed uMRD Placebo arm 67.4 months; uMRD Not Confirmed Ibrutinib arm 47.9 months; uMRD Not Confirmed Ibrutinib + Venetoclax arm 47.9 months.

Time frame:
From randomization date until before any subsequent antineoplastic therapy, for an overall median follow-up of 67.0 months. (Median follow up duration for the individual MRD Cohort treatment arms listed above.)
Reported as:
Number · percentage of participants
MRD Cohort: MRD-Negativity Rate
percentage of participantsMRD Cohort: All TreatedMRD Cohort/uMRD Not Confirmed: All ParticipantsMRD Cohort/uMRD Not Confirmed: Randomized to Open-Label IbrutinibMRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax
PB or BM81.7 (75.8 to 87.6)65.1 (53.3 to 76.9)51.6 (34.0 to 69.2)78.1 (63.8 to 92.4)
BM77.4 (71.0 to 83.8)55.6 (43.3 to 67.8)41.9 (24.6 to 59.3)68.8 (52.7 to 84.8)
PB79.9 (73.7 to 86.0)60.3 (48.2 to 72.4)48.4 (30.8 to 66.0)71.9 (56.3 to 87.5)
SecondaryMRD Cohort: Tumor Lysis Syndrome (TLS) Risk Reduction Rate With 3-Cycle Ibrutinib Lead-In (Percentage of Participants No Longer High Risk After 3-cycle Lead-in)

TLS risk reduction was summarized by the percentage of participants with TLS risk reduced from high at baseline to medium or low after ibrutinib lead-in. A reduction in TLS risk from high risk to medium or low risk is clinically meaningful because there is a reduction in the extent of TLS monitoring and risk of hospitalization. TLS risk category is defined as the tumor burden category, where: Low=All lymph nodes (LN) \< 5 cm AND absolute lymphocyte count (ALC) \< 25 x 10\^9/L; Medium=Any LN 5 cm to \< 10 cm OR ALC ≥ 25 x 10\^9/L; High=Any LN ≥ 10 cm OR ALC ≥ 25 x10\^9/L AND any LN ≥ 5 cm.

Time frame:
Baseline, and last post-baseline value on or prior to venetoclax first dose date (cycle 4 day 1) or, for participants who never received venetoclax, the post-baseline value closest to cycle 4 day 1 (i.e. 84 days after the first dose date of ibrutinib).
Reported as:
Number · percentage of participants
MRD Cohort: Tumor Lysis Syndrome (TLS) Risk Reduction Rate With 3-Cycle Ibrutinib Lead-In (Percentage of Participants No Longer High Risk After 3-cycle Lead-in)
percentage of participantsMRD Cohort: All Treated
MRD Cohort: Tumor Lysis Syndrome (TLS) Risk Reduction Rate With 3-Cycle Ibrutinib Lead-In (Percentage of Participants No Longer High Risk After 3-cycle Lead-in)90.0
SecondaryMRD Cohort: Kaplan-Meier Estimate of Progression Free Survival (PFS) Rate at 48 Months Landmark Time

PFS was defined as time from the first dose date of study treatment until disease progression (PD) or death from any cause, whichever occurs first. Assessment of PD was conducted in accordance with the 2008 IWCLL criteria (Halleck et al). As the median PFS was not reached as of the overall median 67.0 months study follow-up, the Kaplan-Meier estimate of PFS rate at 48 months landmark time was presented. Median follow up duration for the individual MRD Cohort treatment arms: Confirmed uMRD Ibrutinib arm 69.1 months; Confirmed uMRD Placebo arm 67.4 months; uMRD Not Confirmed Ibrutinib arm 47.9 months; uMRD Not Confirmed Ibrutinib + Venetoclax arm 47.9 months.

Time frame:
From the first dose of ibrutinib to the first confirmed PD or death, for an overall median follow-up of 67.0 months. (Median follow up duration for the individual MRD Cohort treatment arms listed above.)
Reported as:
Number · percentage of participants
MRD Cohort: Kaplan-Meier Estimate of Progression Free Survival (PFS) Rate at 48 Months Landmark Time
percentage of participantsMRD Cohort: All TreatedMRD Cohort/Confirmed uMRD: Randomized to Ibrutinib (Blinded)MRD Cohort/Confirmed uMRD: Randomized to Placebo (Blinded)MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label IbrutinibMRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax
MRD Cohort: Kaplan-Meier Estimate of Progression Free Survival (PFS) Rate at 48 Months Landmark Time90.9 (85.1 to 94.5)97.6 (84.3 to 99.7)88.2 (73.9 to 94.9)93.3 (75.9 to 98.3)93.2 (75.5 to 98.3)
SecondaryMRD Cohort: Kaplan-Meier Estimate of Overall Survival (OS) Rate at 48 Months Landmark Time

OS is defined as the time from the first dose date of study treatment until date of death due to any cause. As the median OS was not reached as of the overall median 67.0 months study follow-up, the Kaplan-Meier estimate of OS rate at 48 months landmark time was presented. Median follow up duration for the individual MRD Cohort treatment arms: Confirmed uMRD: Randomized to Ibrutinib=69.1 months; Confirmed uMRD: Randomized to Placebo=67.4 months; uMRD Not Confirmed: Randomized to Open-Label Ibrutinib=47.9 months; uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax=47.9 months.

Time frame:
From the first dose of ibrutinib to time of death, for an overall median follow-up of 67.0 months. (Median follow up duration for the individual MRD Cohort treatment arms listed above.)
Reported as:
Number · percentage of participants
MRD Cohort: Kaplan-Meier Estimate of Overall Survival (OS) Rate at 48 Months Landmark Time
percentage of participantsMRD Cohort: All TreatedMRD Cohort/Confirmed uMRD: Randomized to Ibrutinib (Blinded)MRD Cohort/Confirmed uMRD: Randomized to Placebo (Blinded)MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label IbrutinibMRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax
MRD Cohort: Kaplan-Meier Estimate of Overall Survival (OS) Rate at 48 Months Landmark Time98.0 (94.0 to 99.4)97.6 (84.3 to 99.7)100.0 (100.0 to 100.0)96.7 (78.6 to 99.5)100.0 (100.0 to 100.0)
SecondaryMRD Cohort: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs), and Discontinuations Due to TEAEs

An adverse event (AE) is any untoward medical occurrence, which does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires unplanned in-patient hospitalization \>24 hours or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. Severity of events were graded according to the Common Terminology Criteria for Adverse Events version 4.03: mild=grade1, moderate=grade 2, severe=grade 3, life-threatening=grade 4, death=grade 5. Causal relation of study drug and event was assessed as not related, unlikely, possibly or probably related to the study drug.

Time frame:
From first dose until 30 days following last dose of study drug. Overall median treatment duration for the MRD cohort was 45.1 months.
Reported as:
Number · percentage of participants
MRD Cohort: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs), and Discontinuations Due to TEAEs
percentage of participantsMRD Cohort: All TreatedMRD Cohort/Confirmed uMRD: Randomized to Ibrutinib (Blinded)MRD Cohort/Confirmed uMRD: Randomized to Placebo (Blinded)MRD Cohort/uMRD Not Confirmed: Randomized to Open-Label IbrutinibMRD Cohort/uMRD Not Confirmed: Randomized to Open-Label Ibrutinib + Venetoclax
Any TEAE100.0100.0100.0100.0100.0
Any Grade >=3 TEAE75.683.772.171.078.1
Any Ibrutinib (Ibr)-Related TEAE95.797.793.096.893.8
Any Grade >=3 Ibrutinib-Related TEAE57.955.851.261.362.5
Any Venetoclax (Ven)-Related TEAE81.188.476.780.696.9
Any Grade >=3 Venetoclax-Related TEAE44.551.234.945.256.3
Any TEAE Leading to Ibr or Ven Discontinuation15.916.309.712.5
Any TEAE Leading to Ibr or Ven Discontinuation: Ibr Only10.414.009.73.1
Any TEAE Leading to Ibr or Ven Discontinuation: Ven Only1.22.3000
Any TEAE Leading to Ibr or Ven Discontinuation: Both Ibr and Ven4.30009.4
Any TEAE Leading to Ibr or Ven Dose Reduction26.223.325.625.834.4
Any TEAE Leading to Ibr Only Dose Reduction16.516.311.619.425.0
Any TEAE Leading to Ven Only Dose Reduction4.92.311.603.1
Any TEAE Leading to Both Ibr and Ven Dose Reduction4.94.72.36.56.3
Any SAE34.134.932.641.937.5
Any Grade >= 3 SAE28.732.627.932.328.1
Any SAE Related to Ibr or Ven20.118.614.025.821.9
Any Ibr-related SAE17.114.011.622.618.8
Any Ven-related SAE6.74.77.012.96.3
Fatal TEAE1.22.303.20
Major Hemorrhage TEAE2.42.303.26.3
Grade >= 3 Major Hemorrhage TEAE1.82.303.23.1
Major Hemorrhage SAE2.42.303.26.3
SecondaryFD Cohort: ORR

ORR is defined as the percentage of participants who achieve a best overall response CR, CRi, nPR, PR, or PRL as evaluated by investigator using 2008 IWCLL criteria (Halleck et al.). Participants who did not have any postbaseline response assessment were considered as non-responders. This table is based on response assessments performed on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurs earlier. Kaplan-Meier estimate.

Time frame:
From the first dose of ibrutinib to the first confirmed PD, for a median follow-up of 69.0 months.
Reported as:
Number · percentage of participants
FD Cohort: ORR
percentage of participantsFD Cohort, Non-Del 17p PopulationFixed Duration (FD) Cohort: All Treated
FD Cohort: ORR95.6 (92.1 to 99.0)96.2 (93.3 to 99.2)
SecondaryFD Cohort: DOR at 60 Months Landmark Time

Duration of response was calculated for participants achieving a response (CR, CRi, nPR, PR) based on 2008 IWCLL response criteria (Halleck et al.) and defined as the interval between the date of initial documentation of a response including PR with lymphocytosis, until disease progression (PD) or death from any cause, whichever occurred first. As the median DOR was not reached as of the median 27.9 months study follow-up, the Kaplan-Meier estimate of DOR at 60 months landmark time was presented.

Time frame:
From initial documentation of a response until PD or death from any cause, whichever occurs first, for a median follow-up of 69.0 months.
Reported as:
Number · percentage of participants
FD Cohort: DOR at 60 Months Landmark Time
percentage of participantsFD Cohort, Non-Del 17p PopulationFixed Duration (FD) Cohort: All Treated
FD Cohort: DOR at 60 Months Landmark Time63.6 (54.4 to 71.4)60.5 (52.0 to 68.0)
SecondaryFD Cohort: MRD Negativity Rate

MRD negativity rate is defined as the percentage of participants achieving MRD negativity, which is defined as \<1 CLL cell per 10,000 leukocytes (\<1 x 10\^-4) as assessed by flow cytometry of a peripheral blood (PB) or bone marrow (BM) aspirate sample per central laboratory on or prior to initiation of subsequent antineoplastic therapy or, if applicable, reintroduction of study treatment, whichever occurs earlier.

Time frame:
From randomization date until before any subsequent antineoplastic therapy, for a median follow-up of 69.0 months.
Reported as:
Number · percentage of participants
FD Cohort: MRD Negativity Rate
percentage of participantsFD Cohort, Non-Del 17p PopulationFixed Duration (FD) Cohort: All Treated
BM or PB78.7 (71.8 to 85.6)78.6 (72.2 to 85.0)
BM61.8 (53.6 to 69.9)59.7 (52.1 to 67.4)
PB76.5 (69.3 to 83.6)76.7 (70.2 to 83.3)
SecondaryFD Cohort: Kaplan-Meier Estimate of PFS Rate at 66 Months Landmark Time

PFS was defined as time from the first dose date of study treatment until disease progression (PD) or death from any cause, whichever occurs first. Assessment of PD was conducted in accordance with the 2008 IWCLL criteria (Halleck et al). As the median PFS was not reached as of the median 69.0 months study follow-up, the Kaplan-Meier estimate of PFS rate at 66 months landmark time was presented.

Time frame:
From the first dose of ibrutinib to the first confirmed PD or death, for an median follow-up of 69.0 months.
Reported as:
Median · percentage of participants
FD Cohort: Kaplan-Meier Estimate of PFS Rate at 66 Months Landmark Time
percentage of participantsFD Cohort, Non-Del 17p PopulationFixed Duration (FD) Cohort: All Treated
FD Cohort: Kaplan-Meier Estimate of PFS Rate at 66 Months Landmark Time63.2 (54.1 to 71.0)60.2 (51.7 to 67.7)
SecondaryFD Cohort: Kaplan-Meier Estimate of OS Rate at 66 Months Landmark Time

OS is defined as the time from the first dose date of study treatment until date of death due to any cause. As the median OS was not reached as of the median 69.0 months study follow-up, the Kaplan-Meier estimate of OS rate at 66 months landmark time was presented.

Time frame:
From the first dose of ibrutinib to time of death, for a median follow-up of 69.0 months.
Reported as:
Number · percentage of participants
FD Cohort: Kaplan-Meier Estimate of OS Rate at 66 Months Landmark Time
percentage of participantsFD Cohort, Non-Del 17p PopulationFixed Duration (FD) Cohort: All Treated
FD Cohort: Kaplan-Meier Estimate of OS Rate at 66 Months Landmark Time96.9 (92.1 to 98.8)96.1 (91.4 to 98.2)
SecondaryFD Cohort: TLS Risk Reduction Rate With 3-Cycle Ibrutinib Lead-In (Percentage of Participants No Longer High Risk After 3-cycle Lead-in)

TLS risk reduction was summarized by the percentage of participants with TLS risk reduced from high at baseline to medium or low after ibrutinib lead-in. A reduction in TLS risk from high risk to medium or low risk is clinically meaningful because there is a reduction in the extent of TLS monitoring and risk of hospitalization. TLS risk category is defined as the tumor burden category, where: Low=All lymph nodes (LN) \< 5 cm AND absolute lymphocyte count (ALC) \< 25 x 10\^9/L; Medium=Any LN 5 cm to \< 10 cm OR ALC ≥ 25 x 10\^9/L; High=Any LN ≥ 10 cm OR ALC ≥ 25 x10\^9/L AND any LN ≥ 5 cm.

Time frame:
Baseline, and last post-baseline value on or prior to venetoclax first dose date (cycle 4 day 1) or, for participants who never received venetoclax, the post-baseline value closest to cycle 4 day 1 (i.e. 84 days after the first dose date of ibrutinib).
Reported as:
Number · percentage of participants
FD Cohort: TLS Risk Reduction Rate With 3-Cycle Ibrutinib Lead-In (Percentage of Participants No Longer High Risk After 3-cycle Lead-in)
percentage of participantsFixed Duration (FD) Cohort: All Treated
FD Cohort: TLS Risk Reduction Rate With 3-Cycle Ibrutinib Lead-In (Percentage of Participants No Longer High Risk After 3-cycle Lead-in)94.1
SecondaryFD Cohort: Percentage of Participants With TEAEs, Treatment-Emergent SAEs, and Discontinuations Due to TEAEs

An AE is any untoward medical occurrence, which does not necessarily have a causal relationship with this treatment. An SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires unplanned in-patient hospitalization \>24 hours or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. Severity of events were graded according to the Common Terminology Criteria for Adverse Events version 4.03: mild=grade1, moderate=grade 2, severe=grade 3, life-threatening=grade 4, death=grade 5. Causal relation of study drug and event was assessed as not related, unlikely, possibly or probably related to the study drug.

Time frame:
From first dose until 30 days following last dose of study drug. Overall median treatment duration for the FD cohort was 13.8 months.
Reported as:
Number · percentage of participants
FD Cohort: Percentage of Participants With TEAEs, Treatment-Emergent SAEs, and Discontinuations Due to TEAEs
percentage of participantsFixed Duration (FD) Cohort: All Treated
Any TEAE99.4
Any Grade >=3 TEAE62.3
Any Ibrutinib (Ibr)-Related TEAE92.5
Any Grade >=3 Ibrutinib-Related TEAE44.7
Any Venetoclax (Ven)-Related TEAE84.3
Any Grade >=3 Venetoclax-Related TEAE45.3
Any TEAE Leading to Ibr or Ven Discontinuation5.0
Any TEAE Leading to Ibr or Ven Discontinuation: Ibr Only3.1
Any TEAE Leading to Ibr or Ven Discontinuation: Ven Only0
Any TEAE Leading to Ibr or Ven Discontinuation: Both Ibr and Ven1.9
Any TEAE Leading to Ibr or Ven Dose Reduction20.8
Any TEAE Leading to Ibr Only Dose Reduction5.7
Any TEAE Leading to Ven Only Dose Reduction11.3
Any TEAE Leading to Both Ibr and Ven Dose Reduction3.8
Any SAE23.3
Any Grade >= 3 SAE20.1
Any SAE Related to Ibr or Ven13.8
Any Ibr-related SAE11.9
Any Ven-related SAE8.8
Fatal TEAE0.6
Major Hemorrhage TEAE1.9
Grade >= 3 Major Hemorrhage TEAE1.3
Major Hemorrhage SAE1.3
SecondaryMRD Cohort: Pharmacokinetics (PK) of Ibrutinib When Dosed in Combination With Venetoclax: Observed Maximum Concentration (Cmax)
Time frame:
Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)
Reported as:
Geometric mean · ng/mL
MRD Cohort: Pharmacokinetics (PK) of Ibrutinib When Dosed in Combination With Venetoclax: Observed Maximum Concentration (Cmax)
ng/mLMRD Cohort: All Treated
MRD Cohort: Pharmacokinetics (PK) of Ibrutinib When Dosed in Combination With Venetoclax: Observed Maximum Concentration (Cmax)88.5 ± 74.3
SecondaryMRD Cohort: PK of Ibrutinib When Dosed in Combination With Venetoclax: Time to Cmax (Tmax); Time of Last Measurable Concentration (Tlast); Terminal Elimination Half-Life (t1/2,Term)
Time frame:
Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)
Reported as:
Median · hours
MRD Cohort: PK of Ibrutinib When Dosed in Combination With Venetoclax: Time to Cmax (Tmax); Time of Last Measurable Concentration (Tlast); Terminal Elimination Half-Life (t1/2,Term)
hoursMRD Cohort: All Treated
tmax2.00 (0.970 to 7.00)
tlast24.0 (5.75 to 24.0)
t1/2term5.30 (1.47 to 10.5)
SecondaryMRD Cohort: PK of Ibrutinib When Dosed in Combination With Venetoclax: Area Under the Plasma Concentration-Time Curve (AUC) Over the Last 24-hour Dosing Interval (AUC0-24h); AUC From Time Zero to the Time of Last Quantifiable Concentration (AUClast)
Time frame:
Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)
Reported as:
Geometric mean · ng*h/mL
MRD Cohort: PK of Ibrutinib When Dosed in Combination With Venetoclax: Area Under the Plasma Concentration-Time Curve (AUC) Over the Last 24-hour Dosing Interval (AUC0-24h); AUC From Time Zero to the Time of Last Quantifiable Concentration (AUClast)
ng*h/mLMRD Cohort: All Treated
AUC0-24h504 ± 76.3
AUClast480 ± 78.5
SecondaryMRD Cohort: PK of Ibrutinib When Dosed in Combination With Venetoclax: Terminal Elimination Rate Constant (λz)
Time frame:
Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)
Reported as:
Geometric mean · 1/h
MRD Cohort: PK of Ibrutinib When Dosed in Combination With Venetoclax: Terminal Elimination Rate Constant (λz)
1/hMRD Cohort: All Treated
MRD Cohort: PK of Ibrutinib When Dosed in Combination With Venetoclax: Terminal Elimination Rate Constant (λz)0.132 ± 44.5
SecondaryMRD Cohort: PK of Ibrutinib When Dosed in Combination With Venetoclax: Apparent Total Clearance at Steady-State (CLss/F)
Time frame:
Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)
Reported as:
Geometric mean · L/h
MRD Cohort: PK of Ibrutinib When Dosed in Combination With Venetoclax: Apparent Total Clearance at Steady-State (CLss/F)
L/hMRD Cohort: All Treated
MRD Cohort: PK of Ibrutinib When Dosed in Combination With Venetoclax: Apparent Total Clearance at Steady-State (CLss/F)833 ± 90.9
SecondaryMRD Cohort: PK of Venetoclax When Dosed in Combination With Ibrutinib: Cmax
Time frame:
Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)
Reported as:
Geometric mean · ng/mL
MRD Cohort: PK of Venetoclax When Dosed in Combination With Ibrutinib: Cmax
ng/mLMRD Cohort: All Treated
MRD Cohort: PK of Venetoclax When Dosed in Combination With Ibrutinib: Cmax3034 ± 56.3
SecondaryMRD Cohort: PK of Venetoclax When Dosed in Combination With Ibrutinib: Tmax
Time frame:
Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)
Reported as:
Median · hours
MRD Cohort: PK of Venetoclax When Dosed in Combination With Ibrutinib: Tmax
hoursMRD Cohort: All Treated
MRD Cohort: PK of Venetoclax When Dosed in Combination With Ibrutinib: Tmax6.00 (0.00 to 8.08)
SecondaryMRD Cohort: PK of Venetoclax When Dosed in Combination With Ibrutinib: AUC0-24h
Time frame:
Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)
Reported as:
Geometric mean · ng*h/mL
MRD Cohort: PK of Venetoclax When Dosed in Combination With Ibrutinib: AUC0-24h
ng*h/mLMRD Cohort: All Treated
MRD Cohort: PK of Venetoclax When Dosed in Combination With Ibrutinib: AUC0-24h48993 ± 66.2
SecondaryMRD Cohort: PK of Venetoclax When Dosed in Combination With Ibrutinib: CLss/F
Time frame:
Cycle 6 Day 1: predose, at dose, 1 h (±15 min), 2 h (±15 min), 4 h (±15 min), 6 h (±15 min), 8 h (±15 min)
Reported as:
Geometric mean · L/h
MRD Cohort: PK of Venetoclax When Dosed in Combination With Ibrutinib: CLss/F
L/hMRD Cohort: All Treated
MRD Cohort: PK of Venetoclax When Dosed in Combination With Ibrutinib: CLss/F8.16 ± 69.7

Adverse events

Collected over From first dose until 30 days following last dose of study drug. Overall median treatment duration was 45.1 months for the MRD cohort and 13.8 months for the FD cohort.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FD Cohort: Pre-Dose0/159 (0%)1/159 (0.6%)1/159 (0.6%)
MRD Cohort: Pre-Dose0/164 (0%)2/164 (1.2%)1/164 (0.6%)
FD Cohort: All Participants5/159 (3.1%)37/159 (23.3%)156/159 (98.1%)
MRD Cohort: All Participants3/164 (1.8%)63/164 (38.4%)163/164 (99.4%)
MRD Cohort: Confirmed uMRD (IbrVen->Ibr)1/43 (2.3%)15/43 (34.9%)43/43 (100%)
MRD Cohort: Confirmed uMRD (IbrVen->Pbo)0/43 (0%)14/43 (32.6%)43/43 (100%)
MRD Cohort: uMRD Not Confirmed (IbrVen->Ibr)1/31 (3.2%)13/31 (41.9%)31/31 (100%)
MRD Cohort: uMRD Not Confirmed (IbrVen->IbrVen)0/32 (0%)12/32 (37.5%)32/32 (100%)
FD Cohort: Reintroduced Ibrutinib2/18 (11.1%)6/18 (33.3%)14/18 (77.8%)
FD Cohort: Reintroduced Ibr+Ven0/11 (0%)0/11 (0%)11/11 (100%)
MRD Cohort: Reintroduced Ibrutinib0/7 (0%)1/7 (14.3%)5/7 (71.4%)
MRD Cohort: Reintroduced Ven + Continued Ibr0/2 (0%)0/2 (0%)2/2 (100%)
Most frequent serious events
Showing 10 of 127
Most frequent serious events
EventFD Cohort: Pre-DoseMRD Cohort: Pre-DoseFD Cohort: All ParticipantsMRD Cohort: All ParticipantsMRD Cohort: Confirmed uMRD (IbrVen->Ibr)MRD Cohort: Confirmed uMRD (IbrVen->Pbo)MRD Cohort: uMRD Not Confirmed (IbrVen->Ibr)MRD Cohort: uMRD Not Confirmed (IbrVen->IbrVen)FD Cohort: Reintroduced IbrutinibFD Cohort: Reintroduced Ibr+VenMRD Cohort: Reintroduced IbrutinibMRD Cohort: Reintroduced Ven + Continued Ibr
CELLULITISInfections and infestations0/1590/1644/1591/1641/430/430/310/320/180/111/70/2
PNEUMONIAInfections and infestations0/1590/1643/1599/1643/431/433/312/320/180/110/70/2
FEBRILE NEUTROPENIABlood and lymphatic system disorders0/1590/1641/1594/1640/433/430/310/320/180/110/70/2
NEUTROPENIABlood and lymphatic system disorders0/1590/1641/1592/1640/430/432/310/320/180/110/70/2
TRANSIENT ISCHAEMIC ATTACKNervous system disorders0/1590/1640/1593/1641/430/432/310/320/180/110/70/2
ANGINA PECTORISCardiac disorders0/1590/1640/1590/1640/430/430/310/321/180/110/70/2
OESOPHAGEAL SPASMGastrointestinal disorders0/1590/1640/1590/1640/430/430/310/321/180/110/70/2
PYREXIAGeneral disorders0/1590/1640/1591/1640/430/430/311/321/180/110/70/2
BRONCHITISInfections and infestations0/1590/1641/1590/1640/430/430/310/321/180/110/70/2
COVID-19 PNEUMONIAInfections and infestations0/1590/1640/1591/1641/430/430/310/321/180/110/70/2
Most frequent other events
Showing 10 of 226
Most frequent other events
EventFD Cohort: Pre-DoseMRD Cohort: Pre-DoseFD Cohort: All ParticipantsMRD Cohort: All ParticipantsMRD Cohort: Confirmed uMRD (IbrVen->Ibr)MRD Cohort: Confirmed uMRD (IbrVen->Pbo)MRD Cohort: uMRD Not Confirmed (IbrVen->Ibr)MRD Cohort: uMRD Not Confirmed (IbrVen->IbrVen)FD Cohort: Reintroduced IbrutinibFD Cohort: Reintroduced Ibr+VenMRD Cohort: Reintroduced IbrutinibMRD Cohort: Reintroduced Ven + Continued Ibr
DIARRHOEAGastrointestinal disorders0/1590/16499/159119/16434/4328/4323/3128/323/184/112/72/2
NAUSEAGastrointestinal disorders0/1590/16468/15980/16421/4320/4320/3112/321/182/110/71/2
NEUTROPENIABlood and lymphatic system disorders0/1590/16465/15971/16424/4315/4312/3114/320/180/110/70/2
ARTHRALGIAMusculoskeletal and connective tissue disorders0/1590/16452/15982/16423/4320/4317/3116/322/181/111/70/2
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations0/1590/16439/15973/16421/4322/4314/3111/322/182/111/70/2
ABDOMINAL PAINGastrointestinal disorders1/1590/16413/15928/1648/4310/432/316/322/180/110/71/2
GASTROOESOPHAGEAL REFLUX DISEASEGastrointestinal disorders1/1590/16416/15930/16410/434/436/317/322/181/110/71/2
VOMITINGGastrointestinal disorders0/1590/16433/15942/16413/436/437/3111/320/180/110/71/2
COVID-19Infections and infestations0/1590/1648/15929/16414/4313/432/310/323/182/113/71/2
FATIGUEGeneral disorders0/1590/16439/15956/16414/4321/4310/317/321/181/110/70/2

Baseline characteristics

Age, Customized
Age, Customized(Participants)FD Cohort: All TreatedMRD Cohort: All TreatedTotal
< 65 years114123237
>= 65 years454186
Sex: Female, Male
Sex: Female, Male(Participants)FD Cohort: All TreatedMRD Cohort: All TreatedTotal
Female5361114
Male106103209
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)FD Cohort: All TreatedMRD Cohort: All TreatedTotal
Hispanic or Latino51116
Not Hispanic or Latino149150299
Unknown or Not Reported538
Race (NIH/OMB)
Race (NIH/OMB)(Participants)FD Cohort: All TreatedMRD Cohort: All TreatedTotal
American Indian or Alaska Native011
Asian358
Native Hawaiian or Other Pacific Islander101
Black or African American123
White147147294
More than one race000
Unknown or Not Reported7916
09

Study locations

46 sites
  • City of Hope /ID# 1142-0047
    Duarte, California 91010, United States
  • Moores Cancer Center at UC San Diego /ID# 1142-0241
    La Jolla, California 92093, United States
  • UC Irvine Medical Center - Chao Family Comprehensive Cancer Center /ID# 1142-0008
    Orange, California 92868-3201, United States
  • Norton Cancer Center /ID# 1142-0071
    Louisville, Kentucky 40202, United States
  • Rutgers Cancer Institute of New Jersey /ID# 1142-1193
    New Brunswick, New Jersey 08901, United States
  • Northwell Health/Long Island Jewish Hospital /ID# 1142-0350
    New Hyde Park, New York 11042, United States
  • New York Presbyterian Hospital/Weill Cornell Med College /ID# 1142-0200
    New York, New York 10021, United States
  • University of Rochester Cancer Center /ID# 1142-0127
    Rochester, New York 14642-0001, United States
  • Charlotte-Mecklenberg Hospital, Carolinas Healthcare System, Levine Cancer Inst /ID# 1142-0733
    Charlotte, North Carolina 28203, United States
  • Cleveland Clinic Foundation /ID# 1142-0739
    Cleveland, Ohio 44195, United States
  • University of Pennsylvania /ID# 1142-0069
    Philadelphia, Pennsylvania 19104, United States
  • Tennessee Oncology - Chattanooga /ID# 1142-0123
    Chattanooga, Tennessee 37404-1108, United States
  • MD Anderson Cancer Center /ID# 1142-0032
    Houston, Texas 77030, United States
  • Swedish Cancer Institute /ID# 1142-0114
    Seattle, Washington 98104, United States
  • St George Hospital /ID# 1142-0654
    Kogarah, New South Wales 2217, Australia
  • Flinders Medical Centre /ID# 1142-0163
    Bedford Park, South Australia 5042, Australia
  • Monash Medical Centre /ID# 1142-0556
    Clayton, Victoria 3168, Australia
  • Peter MacCallum Cancer Centre-East Melbourne /ID# 1142-0633
    East Melbourne, Victoria 3002, Australia
  • St Vincent's Hospital Melbourne /ID# 1142-0501
    Fitzroy, Victoria 3065, Australia
  • Frankston Hospital /ID# 1142-0715
    Frankston, Victoria 3199, Australia
  • Austin Health /ID# 1142-0170
    Heidelberg, Victoria 3084, Australia
  • Ospedale San Raffaele IRCCS /ID# 1142-0523
    Milan, Lombardy 20132, Italy
  • Ospedale Policlinico San Martino /ID# 1142-0903
    Genova, 16132, Italy
  • ASST Grande Ospedale Metropolitano Niguarda /ID# 1142-0581
    Milan, 20162, Italy
  • Azienda Ospedaliero-Universitaria di Modena /ID# 1142-0524
    Modena, 41124, Italy
  • Azienda Ospedaliero Universitaria Maggiore della Carita di Novara /ID# 1142-0582
    Novara, 28100, Italy
  • Azienda Ospedaliera di Padova /ID# 1142-1175
    Padova, 35128, Italy
  • Azienda USL di Piacenza - Ospedale Guglielmo da Saliceto /ID# 1142-1182
    Piacenza, 29121, Italy
  • Middlemore Hospital /ID# 1142-0662
    Otahuhu, Auckland 2025, New Zealand
  • Christchurch Hospital /ID# 1142-0589
    Christchurch, Canterbury 8011, New Zealand
  • Palmerston North Hospital /ID# 1142-0585
    Palmerston North, Manawatu-Wanganui 4414, New Zealand
  • North Shore Hospital /ID# 1142-0663
    Auckland, 0622, New Zealand
  • Malopolskie Centrum Medyczne /ID# 1142-0364
    Krakow, Lesser Poland Voivodeship 30-510, Poland
  • Duplicate_Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie /ID# 1142-0590
    Lublin, Lublin Voivodeship 20-081, Poland
  • Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im. ks. B. /ID# 1142-0592
    Brzozów, Podkarpackie Voivodeship 36-200, Poland
  • Samodzielny Publiczny Szpital Klinczny Nr-1- Akademickie Cenrum Klinic /ID# 1142-0529
    Gdansk, Pomeranian Voivodeship 80-952, Poland
  • Medical Univ. of Lodz and Copernicus Memorial Hospital /ID# 1142-0531
    Lodz, 93-510, Poland
  • Hospital Duran i Reynals /ID# 1142-0604
    L'Hospitalet de Llobregat, Barcelona 08907, Spain
  • Hospital Universitario Puerta de Hierro, Majadahonda /ID# 1142-0536
    Majadahonda, Madrid 28222, Spain
  • Complejo Hospitalario de Navarra /ID# 1142-1197
    Pamplona, Navarre 31008, Spain
  • Hospital Clinic de Barcelona /ID# 1142-0533
    Barcelona, 08036, Spain
  • Hospital Santa Creu i Sant Pau /ID# 1142-0535
    Barcelona, 08041, Spain
  • Hospital Universitario Virgen de las Nieves /ID# 1142-1196
    Granada, 18014, Spain
  • Hospital Universitario Ramon y Cajal /ID# 1142-0874
    Madrid, 28034, Spain
  • Hospital Universitario 12 de Octubre /ID# 1142-0864
    Madrid, 28041, Spain
  • Hospital Clinico Universitario de Salamanca /ID# 1142-0790
    Salamanca, 37007, Spain
10

References and documents

Publications

  • Castonguay M, Anderson MA, Thompson P, Seymour JF. Venetoclax retreatment in chronic lymphocytic leukemia is biologically rational and clinically effective. Blood Adv. 2026 May 26;10(10):3357-3366. doi: 10.1182/bloodadvances.2026019871. PubMed 41843779 ↗
  • Moreno C, Solman IG, Tam CS, Grigg A, Scarfo L, Kipps TJ, Srinivasan S, Mali RS, Zhou C, Dean JP, Szafer-Glusman E, Choi M. Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study. Blood Adv. 2023 Sep 26;7(18):5294-5303. doi: 10.1182/bloodadvances.2023010236. PubMed 37315225 ↗
  • Wierda WG, Allan JN, Siddiqi T, Kipps TJ, Opat S, Tedeschi A, Badoux XC, Kuss BJ, Jackson S, Moreno C, Jacobs R, Pagel JM, Flinn I, Pak Y, Zhou C, Szafer-Glusman E, Ninomoto J, Dean JP, James DF, Ghia P, Tam CS. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. J Clin Oncol. 2021 Dec 1;39(34):3853-3865. doi: 10.1200/JCO.21.00807. Epub 2021 Oct 7. PubMed 34618601 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Nov 2020, 49 months.

Results were first posted in Feb 2022, 1 year 3 months after primary completion.

Of 41 industry-sponsored phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 87. This study's 49 months is below that.

Counting every sponsor, half of 249 studies reached it within 73 months; a quarter within 41 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2016
First posted
Sep 22, 2016
StartActual
Sep 28, 2016
Primary completionActual
Nov 12, 2020
CompletionActual
Mar 27, 2024
Results first posted
Feb 18, 2022
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02910583
Lead sponsor
Pharmacyclics LLC.
Responsible party
Sponsor
First posted
Sep 22, 2016
Start date
Sep 28, 2016
Primary completion
Nov 12, 2020
Completion
Mar 27, 2024
Results posted
Feb 18, 2022
Last update
Sep 10, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ibrutinib · Venetoclax

Start the discussion